Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

[French ccAFU guidelines - Update 2018-2020: Management of kidney cancer].

Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Correas JM, Gimel P, Hetet JF, Long JA, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Méjean A.

Prog Urol. 2018 Nov;28 Suppl 1:R5-R33. doi: 10.1016/j.purol.2019.01.004. Epub 2019 Aug 23. French.

PMID:
31610874
2.

The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma.

McKay RR, Vu P, Albiges LK, Lin X, Simantov R, Temel JS, Choueiri TK.

Clin Genitourin Cancer. 2019 Jul 19. pii: S1558-7673(19)30220-4. doi: 10.1016/j.clgc.2019.07.004. [Epub ahead of print]

PMID:
31601515
3.

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B.

Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1. Review.

PMID:
31377308
4.

Renal Cell Carcinoma with bone metastases isn't always bad.

Ruatta F, Albiges L, Derosa L.

Oncotarget. 2019 Jul 16;10(44):4511-4512. doi: 10.18632/oncotarget.27076. eCollection 2019 Jul 16. No abstract available.

5.

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C.

Eur Urol Oncol. 2019 Jul 19. pii: S2588-9311(19)30099-9. doi: 10.1016/j.euo.2019.06.018. [Epub ahead of print]

PMID:
31331862
6.

Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40].

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Sep;119:200-201. doi: 10.1016/j.ejca.2019.04.012. Epub 2019 Jul 11. No abstract available.

PMID:
31301937
7.

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.

Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. Epub 2019 May 25.

PMID:
31229459
8.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L.

J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.

PMID:
31194611
9.

Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.

Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH, Hofmann F, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A, Bensalah K.

Eur Urol Oncol. 2019 Jun 3. pii: S2588-9311(19)30054-9. doi: 10.1016/j.euo.2019.04.005. [Epub ahead of print] Review.

PMID:
31171501
10.

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A.

Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022.

PMID:
31151678
11.

Body Mass Index and Outcomes in Germ-Cell Tumors.

McGregor BA, Miller RE, O'Donnell E, Albiges LK, Sweeney CJ, Markt SC.

Clin Genitourin Cancer. 2019 Aug;17(4):283-290. doi: 10.1016/j.clgc.2019.04.012. Epub 2019 Apr 25.

PMID:
31129146
12.

Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers.

Briganti A, Albiges L, Giannarini G, Kamat AM, Nguyen PL.

Eur Urol Oncol. 2018 May;1(1):1-2. doi: 10.1016/j.euo.2018.04.002. Epub 2018 May 15. No abstract available.

PMID:
31100222
13.

[Testicular tumors: A diagnostic challenge of imaging].

Rocher L, Ksouri A, Maxwell F, Bresson B, Hindawi G, Balasa C, Bellin MF, Albiges L.

Bull Cancer. 2019 Oct;106(10):875-886. doi: 10.1016/j.bulcan.2019.03.008. Epub 2019 May 12. Review. French.

PMID:
31088679
14.

Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification.

Boissier R, Ouzaid I, Nouhaud FX, Khene Z, Dariane C, Chkir S, Chelly S, Giwerc A, Allenet C, Lefrancq JB, Gimel P, Bodin T, Rioux-Leclercq N, Correas JM, Albiges L, Hetet JF, Bigot P, Bernhard JC, Long JA, Mejean A, Bensalah K; AFU Committee of Urological Oncology.

Int Urol Nephrol. 2019 Jun;51(6):951-958. doi: 10.1007/s11255-019-02085-6. Epub 2019 Apr 12.

PMID:
30977021
15.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A.

Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.

PMID:
30803729
16.

A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment.

Vicier C, Baciarello G, Arfi-Rouche J, Massard C, Loriot Y, Albiges L, Cojean-Zelek I, Fizazi K.

Clin Genitourin Cancer. 2019 Jun;17(3):e485-e487. doi: 10.1016/j.clgc.2019.01.010. Epub 2019 Jan 26. No abstract available.

PMID:
30792009
17.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

18.

Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab.

Dutertre M, de Menthon M, Noël N, Albiges L, Lambotte O.

Eur J Cancer. 2019 Mar;110:21-23. doi: 10.1016/j.ejca.2019.01.009. Epub 2019 Feb 7. No abstract available.

PMID:
30739836
19.

A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.

Derosa L, Bayar MA, Albiges L, Le Teuff G, Escudier B.

Angiogenesis. 2019 Aug;22(3):383-395. doi: 10.1007/s10456-019-09664-2. Epub 2019 Feb 9.

PMID:
30739258
20.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5. Erratum in: Eur J Cancer. 2019 Sep;119:200-201.

PMID:
30616146
21.

Characterization of Testicular Masses in Adults: Performance of Combined Quantitative Shear Wave Elastography and Conventional Ultrasound.

Rocher L, Criton A, Gennisson JL, Creze M, Albiges L, Ferlicot S, Bellin MF, Izard V, Correas JM.

Ultrasound Med Biol. 2019 Mar;45(3):720-731. doi: 10.1016/j.ultrasmedbio.2018.10.027. Epub 2018 Dec 29.

PMID:
30600129
22.

Traitement des métastases osseuses du cancer du rein.

Guida A, Albiges L.

Bull Cancer. 2018 Dec;105 Suppl 3:S268-S279. doi: 10.1016/S0007-4551(18)30382-5. Review. French.

PMID:
30595156
23.

Les métastases cérébrales de cancer du rein, un défi clinique.

Flippot R, Derosa L, Albiges L.

Bull Cancer. 2018 Dec;105 Suppl 3:S261-S267. doi: 10.1016/S0007-4551(18)30381-3. Review. French.

PMID:
30595155
24.

Cancer du rein : tendances et perspectives.

Mery B, Thiery-Vuillemin A, Massard C, Albiges L, Magné N.

Bull Cancer. 2018 Dec;105 Suppl 3:S219-S220. doi: 10.1016/S0007-4551(18)30375-8. French.

PMID:
30595149
25.

Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.

Ruatta F, Derosa L, Escudier B, Colomba E, Guida A, Baciarello G, Loriot Y, Fizazi K, Albiges L.

Eur J Cancer. 2019 Jan;107:79-85. doi: 10.1016/j.ejca.2018.10.023. Epub 2018 Dec 11.

PMID:
30551078
26.

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Albiges L, Stewart F, Volpe A, Graser A, Schlemmer M, Yuan C, Lam T, Staehler M.

Clin Genitourin Cancer. 2019 Apr;17(2):e345-e355. doi: 10.1016/j.clgc.2018.07.024. Epub 2018 Aug 11.

PMID:
30528378
27.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.

Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.

PMID:
30528137
28.

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du reinFrench ccAFU guidelines – Update 2018–2020: Management of kidney cancer

Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Correas JM, Gimel P, Hetet JF, Long JA, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Méjean A.

Prog Urol. 2018 Nov;28(12S):S3-S31. doi: 10.1016/j.purol.2018.09.009. Epub 2018 Oct 26. Review. French. Erratum in: Prog Urol. 2018 Nov;28 Suppl 1:R5-R33.

PMID:
30473002
29.

Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.

Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A.

Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25.

PMID:
30467042
30.

Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light.

Albiges L, Flippot R, Rioux-Leclercq N, Choueiri TK.

J Clin Oncol. 2018 Oct 29:JCO2018792531. doi: 10.1200/JCO.2018.79.2531. [Epub ahead of print]

PMID:
30372389
31.

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.

Lalani AA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A.

Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13. Review.

PMID:
30327274
32.

Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.

Lebacle C, Bensalah K, Bernhard JC, Albiges L, Laguerre B, Gross-Goupil M, Baumert H, Lang H, Tricard T, Duclos B, Arnoux A, Piedvache C, Patard JJ, Escudier B.

BJU Int. 2019 May;123(5):804-810. doi: 10.1111/bju.14581. Epub 2018 Nov 20.

PMID:
30288884
33.

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.

Guillot A, Joly C, Barthélémy P, Meriaux E, Negrier S, Pouessel D, Chevreau C, Mahammedi H, Houede N, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Culine S, Fizazi K.

Clin Genitourin Cancer. 2019 Feb;17(1):e38-e43. doi: 10.1016/j.clgc.2018.08.006. Epub 2018 Sep 6.

PMID:
30279115
34.

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T.

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7. No abstract available.

PMID:
30201510
35.

Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.

Flippot R, Escudier B, Albiges L.

Drugs. 2018 Sep;78(14):1443-1457. doi: 10.1007/s40265-018-0970-y. Review.

PMID:
30187355
36.

Treating patients with renal cell carcinoma and bone metastases.

Guida A, Escudier B, Albiges L.

Expert Rev Anticancer Ther. 2018 Nov;18(11):1135-1143. doi: 10.1080/14737140.2018.1520097. Epub 2018 Sep 13. Review.

PMID:
30183421
37.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Staehler M, Volpe A, Powles T.

Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.

PMID:
30177291
38.

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic.

Patrikidou A, Maroun P, Patard JJ, Baumert H, Albiges L, Massard C, Loriot Y, Escudier B, Di Palma M, Arfi-Rouche J, Rocher L, Merabet Z, Bossi A, Fizazi K, Blanchard P.

Clin Transl Radiat Oncol. 2018 Jul 6;12:28-33. doi: 10.1016/j.ctro.2018.07.001. eCollection 2018 Aug.

39.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Nov 15;24(22):5534-5542. doi: 10.1158/1078-0432.CCR-18-1045. Epub 2018 Jul 30.

PMID:
30061359
40.

Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.

Meyer E, Pasquier D, Bernadou G, Calais G, Maroun P, Bossi A, Theodore C, Albiges L, Stefan D, de Crevoisier R, Hennequin C, Lagrange JL, Grellard JM, Clarisse B, Licaj I, Habrand JL, Carrie C, Joly F.

Eur J Cancer. 2018 Jul;98:38-47. doi: 10.1016/j.ejca.2018.04.008. Epub 2018 Jun 1.

PMID:
29864737
41.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

42.

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).

Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate. 2018 Sep;78(12):889-895. doi: 10.1002/pros.23645. Epub 2018 Apr 29.

43.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

44.

Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors.

Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, Garcia J, Dreicer R, Escudier B, Rini B.

Clin Genitourin Cancer. 2018 Jun;16(3):e663-e667. doi: 10.1016/j.clgc.2017.12.014. Epub 2018 Jan 4.

PMID:
29428404
45.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.

PMID:
29331748
46.

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.

47.

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi: 10.1016/j.eururo.2017.11.016. [Epub ahead of print]

PMID:
29223605
48.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765. doi: 10.1093/annonc/mdx774.

PMID:
29216400
49.

ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.

Urun Y, Leow JJ, Fay AP, Albiges L, Choueiri TK, Bellmunt J.

Crit Rev Oncol Hematol. 2017 Dec;120:120-126. doi: 10.1016/j.critrevonc.2017.10.012. Epub 2017 Nov 2. Review.

PMID:
29198325
50.

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L.

Eur J Cancer. 2017 Dec;87:147-163. doi: 10.1016/j.ejca.2017.10.014. Epub 2017 Nov 14.

PMID:
29149761

Supplemental Content

Loading ...
Support Center